References
- Goodman CS . HTA 101: II. fundamental concepts. 2014 [updated 2019 Nov 21; Cited 2022 Nov 21]. Available from: https://www.nlm.nih.gov/nichsr/hta101/ta10103.html
- Drummond MF, Schwartz JS, Jönsson B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care. 2008;24(3):244–258.
- Nicod E, Annemans L, Bucsics A, et al. HTA programme response to the challenges of dealing with orphan medicinal products: process evaluation in selected European countries. Health Policy. 2019;123(2):140–151.
- Lancet diabetes & endocrinology T, The Lancet. Spotlight on rare diseases [Editorial]. Lancet Diabetes Endocrinol. 2019;7:75.
- D’Amico A, Mercuri E, Tiziano FD, et al. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6:71.
- Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;371:2120–2133.
- European Commission (EC). Rare Diseases - A major unmet medical need. Brussels: Publications Office of the EU; 2017 Nov 07 [cited 2023 Mar 17]. Available from: https://op.europa.eu/en/publication-detail/-/publication/c2ba4fd4-ae31-11e7-837e-01aa75ed71a1
- Drummond MF, Wilson DA, Kanavos P, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23:36–42.
- Chambers JD, Silver MC, Berklein FC, et al. Orphan drugs offer larger health gains but less favorable cost-effectiveness than non-orphan drugs. J Gen Intern Med. 2020;35:2629–2636.
- Hughes-Wilson W, Palma A, Schuurman A, et al. Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7:74.
- Landfeldt E, Pechmann A, McMillan HJ, et al. Costs of illness of spinal muscular atrophy: a systematic review. Appl Health Econ Health Policy. 2021;19:501–520.
- Paracha N, Hudson P, Mitchell S, et al. Systematic literature review to assess the cost and resource use associated with spinal muscular atrophy management. Pharmacoeconomics. 2022;40(S1):11–38.
- Michel M, Toumi M. Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoeconomics Outcomes Res. 2012;12:23–29.
- Lucas F. Improving market access to rare disease therapies: a worldwide perspective with recommendations to the industry. Med Access Point of Care. 2018;2:1–7.
- NHS England strikes deal on life-saving gene-therapy drug that can help babies with rare genetic disease move and walk. 2021 Mar 8 [cited 2022 Sep 26]. Available from: https://www.england.nhs.uk/2021/03/nhs-england-strikes-deal-on-life-saving-gene-therapy-drug-that-can-help-babies-with-rare-genetic-disease-move-and-walk/
- Whittal A, Meregaglia M, Nicod E. The use of patient-reported outcome measures in rare diseases and implications for health technology assessment. Patient. 2021;14:485–503.
- Meregaglia M, Nicod E, Drummond M. The estimation of health state utility values in rare diseases: overview of existing techniques. Int J Technol Assess Health Care. 2020;36:469–73.
- Sutherland CS, Hudson P, Mitchell S, et al. Systematic literature review to identify utility values in patients with Spinal Muscular Atrophy (SMA) and their caregivers. Pharmacoeconomics. 2022;40(Suppl S1):39–67.
- Institute for Clinical and Economic Review (ICER). Spinraza® and Zolgensma® for spinal muscular atrophy: effectiveness and value. 2019 Apr 3 [cited 2023Mar17] . Available from: https://icer.org/wp-content/uploads/2020/10/ICER_SMA_Final_Evidence_Report_110220.pdf
- National Institute for Health and Care Excellence (NICE). Nusinersen for treating spinal muscular atrophy [TA588]. 2019 Jul 24 [cited 2022 Sep 26]. Available from: https://www.nice.org.uk/guidance/ta588/history
- Messina S, Sframeli M. New treatments in spinal muscular atrophy: positive results and new challenges. J Clin Med. 2020;9:2222.
- National Institute for Health and Care Excellence (NICE). Onasemnogene abeparvovec for treating spinal muscular atrophy [HST15]. 2021 Jul 7 [cited 2022 Sep 26]. Available from: https://www.nice.org.uk/guidance/hst15/history
- Jablonka S, Hennlein L, Sendtner M. Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders. Neurol Res Pract. 2022;4:2.
- Ratni H, Ebeling M, Baird J, et al. Discovery of risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) gene splicing modifier for the treatment of Spinal Muscular Atrophy (SMA). J Med Chem. 2018;61:6501–17.
- National Institute for Health and Care Excellence (NICE).Onasemnogene abeparvovec for treating pre-symptomatic spinal muscular atrophy (partial review of HST15). Final draft guidance.2023 Mar 16 [cited 2023 Mar 17]. Available from: https://www.nice.org.uk/guidance/gid-hst10053/documents/final-evaluation-determination-document
- National Institute for Health and Care Excellence (NICE). Risdiplam for treating spinal muscular atrophy [TA755]. 2021 Dec 16 [cited 2022 Sep 26]. Available from: https://www.nice.org.uk/guidance/ta755/history
- National Institute for Health and Care Excellence (NICE). Final appraisal document: nusinersen for treating spinal muscular atrophy [TA588]. 2019 Jul [cited 2022 Sep 26] . Available from: https://www.nice.org.uk/guidance/ta588/documents/final-appraisal-determination-document-2
- ISPOR. Delivering evidence-based access in rare diseases: the challenges in SMA. 2022 Apr 05 [cited 2022 Sep 26]. Available from: https://www.ispor.org/conferences-education/education-training/webinars/webinar/delivering-evidence-based-access-in-rare-diseases-the-challenges-in-sma
- European Commission (EC) [Internet]. Union Register of medicinal products for human use. European Commission procedures: Zolgensma. [updated 2022 Sep 12; cited 2022 Sep 26]. Available from: https://ec.europa.eu/health/documents/community-register/html/h1443.htm
- European Commission (EC) [Internet]. Union Register of medicinal products for human use. European Commission procedures: Evrysdi. [updated 2022 Sep 26; cited 2022 Sep 26]. Available from: https://ec.europa.eu/health/documents/community-register/html/h1531.htm
- European Commission (EC) [Internet]. Union Register of medicinal products for human use. European Commission procedures: Spinraza. [updated 2022 Apr 4; cited 2022 Sep 26]. Available from: https://ec.europa.eu/health/documents/community-register/html/h1188.htm
- National Institute for Health and Care Excellence (NICE). Final appraisal document: risdiplam for treating spinal muscular atrophy [TA755]. 2021 Nov [cited 2022 Sep 26] . Available from: https://www.nice.org.uk/guidance/ta755/documents/final-appraisal-determination-document-6
- National Institute for Health and Care Excellence (NICE). Final evaluation document: onasemnogene abeparvovec for treating spinal muscular atrophy [HST15]. 2021 May [cited 2022 Sep 26] . Available from: https://www.nice.org.uk/guidance/hst15/documents/final-evaluation-determination-document
- Novartis Gene Therapies. Highly specialised technology evaluation Onasemnogene abeparvovec for treating pre-symptomatic spinal muscular atrophy (MAA partial review of HST 15) [ID4051]. Document B Company evidence submission. 2022 Aug 11 [cited 2022 Mar 17]. Available from https://www.nice.org.uk/guidance/gid-hst10053/documents/committee-papers
- Novartis Gene Therapies. Highly specialised technologies evaluation programme. INTERIM. ZOLGENSMA® (onasemnogene abeparvovec) for treating spinal muscular atrophy type 1 [ID1473]. Specification for company submission of evidence: supplementary Appendix. 2020 May 1 [cited 2022 Sep 26] . Available from: https://www.nice.org.uk/guidance/hst15/documents/committee-papers
- Roche Products. Single technology appraisal. ID1631: risdiplam for treating spinal muscular atrophy in children and adults. Document B: company evidence submission. 2020 Oct 30 cited 2022 Sep 26] . Available from: https://www.nice.org.uk/guidance/ta755/documents/committee-papers
- Biogen International GmbH. Single technology appraisal: nusinersen for treating spinal muscular atrophy [ID1069]. Document B: company evidence submission. 2018 Mar 15 cited 2022 Sep 26] . Available from: https://www.nice.org.uk/guidance/ta588/documents/committee-papers
- Tappenden P, Hock E Nusinersen for treating spinal muscular atrophy: a single technology appraisal. Addendum 2: ERG comments on company’s revised models and additional economic analyses. Sheffield: School of Health and Related Research (ScHARR), The University of Sheffield; 2019 Feb 22 [cited 2022 Sep 26] . Available from: https://www.nice.org.uk/guidance/ta588/documents/committee-papers-4
- Products R. Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]. Roche technical engagement response form. 2021 Mar 10 [cited 2022 Sep 26] . Available from: https://www.nice.org.uk/guidance/ta755/documents/committee-papers
- Tappenden P, Hock E, Hamilton J, et al. Nusinersen for treating spinal muscular atrophy: a Single Technology Appraisal. Addendum - ERG commentary on company’s ACD response . Sheffield: School of Health and Related Research (ScHARR), The University of Sheffield [cited 2022 Sep 22]. Available from: https://www.nice.org.uk/guidance/ta588/documents/committee-papers-4
- Roche Products. Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]. Roche ACD stakeholder comments. 2021 Jun cited 2022 Sep 26] . Available from: https://www.nice.org.uk/guidance/ta755/documents/committee-papers-3
- Tappenden P, Navega Biz A, Hock E Risdiplam for treating spinal muscular atrophy: a single technology appraisal. Addendum: ERG’s comments on the company’s ACD response. Sheffield: School of Health and Related Research (ScHARR), The University of Sheffield; 2021 Jul 6 [cited 2022 Sep 26] . Available from: https://www.nice.org.uk/guidance/ta755/documents/committee-papers-3
- Tappenden P, Hock E, Stevens J, et al. Risdiplam for treating spinal muscular atrophy: a single technology appraisal. Sheffield: School of Health and Related Research (ScHARR), The University of Sheffield; 2021 Feb 3 [cited 2022 Sep 26] . Available from: https://www.nice.org.uk/guidance/ta755/documents/committee-papers
- Khan KA, Petrou S, Rivero-Arias O, et al. Mapping EQ-5D utility scores from the PedsQL™ generic core scales. Pharmacoeconomics. 2014;32:693–706.
- Lloyd A, Gallop K, Thompson R, et al. Estimation of the health-related quality of life benefits of treatment for Spinal Muscular Atropy (SMA). Value Health. 2017;20:A559.
- Biogen International GmbH. Nusinersen (SPINRAZA®) for the treatment of 5q spinal muscular atrophy. supplementary appendix 2: cost-effectiveness model revisions and updated results [cited 2022 Sep 26]. Available from: https://www.nice.org.uk/guidance/ta588/documents/committee-papers-4
- López-Bastida J, Peña-Longobardo LM, Aranda-Reneo I, et al. Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain. Orphanet J Rare Dis. 2017;12:141.
- Novartis Gene Therapies. Highly specialised technologies evaluation programme. INTERIM. ZOLGENSMA® (onasemnogene abeparvovec) for treating spinal muscular atrophy type 1 [ID1473]. Specification for company submission of evidence: supplementary Appendix. 2019 Aug 19 [cited 2022 Sep 26] . Available from: https://www.nice.org.uk/guidance/hst15/documents/committee-papers
- Lloyd AJ, Thompson R, Gallop K, et al. Estimation of the quality of life benefits associated with treatment for spinal muscular atrophy. ClinicoEconomics Outcomes Res. 2019;11:615–22.
- Tappenden P, Hock E, Stevens J, et al. Risdiplam for treating spinal muscular atrophy: a single technology appraisal. Addendum: ERG comments on company’s technical engagement response. Sheffield: School of Health and Related Research (ScHARR), The University of Sheffield; 2021 Mar 22 [cited 2022 Sep 26] . Available from: https://www.nice.org.uk/guidance/ta755/documents/committee-papers
- Bovenberg J, Penton H, Buyukkaramikli N. 10 Years of End-of-Life Criteria in the United Kingdom. Value Health. 2021;24:691–698.
- Wirth B, Karakaya M, Kye MJ, et al. Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next. Annu Rev Genomics Hum Genet. 2020;21:231–61.
- Chen TH. New and developing therapies in spinal muscular atrophy: from genotype to phenotype to treatment and where do we stand? Int J Mol Sci. 2020;21:3297.
- Tizzano EF, Finkel RS. Spinal muscular atrophy: a changing phenotype beyond the clinical trials. Neuromuscul Disord. 2017;27:883–9.
- Mercuri E, Pera MC, Scoto M, et al. Spinal muscular atrophy — insights and challenges in the treatment era. Nat Rev Neurol. 2020;16:706–715.
- Talbot K, Tizzano EF. The clinical landscape for SMA in a new therapeutic era. Gene Ther. 2017;24:529–533.
- Paracha N, Hudson P, Mitchell S, et al. Systematic literature review to assess economic evaluations in Spinal Muscular Atrophy (SMA). Pharmacoeconomics. 2022;40(S1):69–89.
- Managed Access Oversight Committee (MAOC). Recommendations from the managed access oversight committee: nusinersen for treating spinal muscular atrophy [NICE Technology Appraisal 588] Managed Access Agreement. Clinical eligibility criteria evidence review. 2021 Mar 8 [cited 2022 Sep 26] . Available from: https://www.nice.org.uk/guidance/ta588/evidence/managed-access-oversight-committee-maoc-recommendation-report-pdf-9138885233
- Kang J, Cairns J “Don’t think twice, it’s all right”: using additional data to reduce uncertainty regarding oncologic drugs provided through managed access agreements in England. Pharmacoeconomics. 2023;2:77–91
- National Institute for Health and Care Excellence (NICE). Real-world evidence framework. 2022 Jun 23 [cited 2022 Sep 26]. Available from: https://www.nice.org.uk/corporate/ecd9/chapter/overview
- Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy. 2015;119:964–979.
- Tisdale A, Cutillo CM, Nathan R, et al. The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems. Orphanet J Rare Dis. 2021;16:429.
- Nicod E, Meregaglia M, Whittal A, et al. Consideration of quality of life in the health technology assessments of rare disease treatments. Eur J Health Econ. 2022;23:645–69.
- National Institute for Health and Care Excellence (NICE). NICE health technology evaluations: the manual. 2022 Jan 31 [cited 2022Sep 26] . Available from: https://www.nice.org.uk/process/pmg36/resources/nice-health-technology-evaluations-the-manual-pdf-72286779244741
- EuroQol [Internet]. EQ-5D-Y (Youth) | about. [ updated 2021 Nov 30; cited 2022 Sep 26]. Available from: https://euroqol.org/eq-5d-instruments/eq-5d-y-about/
- EuroQol [Internet]. Status of EQ-5D-Y valuation using standardized valuation methodology. 2022 [updated 2022 Mar 07; cited 2022 Sep 30]. Available from: https://euroqol.org/wp-content/uploads/2021/01/Overview-of-youth-valuation-studies_worldmap-7mar2022.pdf
- Ara R, Brazier J, Zouraq IA. The use of health state utility values in decision models. Pharmacoeconomics. 2017;35(S1):77–88.
- Pennington B, Wong R Modelling carer health-related quality of life in NICE technology appraisals and highly specialised technologies. 2019 Apr 3 [cited 2023 Mar17] . Available from: https://www.sheffield.ac.uk/nice-dsu/methods-development
- Pennington BM. Inclusion of carer health-related quality of life in national institute for health and care excellence appraisals. Value Health. 2020;23:1349–1357.
- UK National Screening Committee. Antenatal and newborn screening programme: SMA [ cited 2022 Sep 26]. cited: https://view-health-screening-recommendations.service.gov.uk/sma/
- Gregoretti C, Ottonello G, Chiarini Testa MB, et al. Survival of patients with spinal muscular atrophy type 1. Pediatrics. 2013;131:e1509–14.
- Kolb SJ, Coffey CS, Yankey JW, et al., NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker InvestigatorsNeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators. Ann Neurol. 2017;82(6):883–891.
- Chaytow H, Faller KME, Huang Y-T, et al. Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine. Cell Rep Med. 2021;2:100346.
- Wijngaarde C A, Stam M, Otto LAM, et al. Muscle strength and motor function in adolescents and adults with spinal muscular atrophy. Neurology. 2020;95(14):e1988–e1998. DOI:10.1212/WNL.0000000000010540.
- Zerres K, Rudnik-Schöneborn S, Forrest E, et al. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. Journal of the Neurological Sciences. 1997;146(1):67–72. DOI:10.1016/S0022-510X(96)00284-5.
- Biogen International GmbH. [ID1069] Nusinersen (SPINRAZA®) for the treatment of 5q spinal muscular atrophy. Cost-effectiveness model revisions and updated results – addendum 1. 2019 [cited 2022 Sep 26]. Available from: https://www.nice.org.uk/guidance/ta588/documents/committee-papers-4
- Edwards SJ, Barton S, Jhita T, et al. Onasemnogene abeparvovec for treating spinal muscular atrophy: a highly specialised technology appraisal. London: BMJ Technology Assessment Group; 2020 Aug 28 [cited 2022 Sep 26] . Available from: https://www.nice.org.uk/guidance/hst15/documents/committee-papers
- Noyes J, Godfrey C and Beecham J. (2006). Resource use and service costs for ventilator-dependent children and young people in the UK. Health Soc Care Community, 14(6), 508–522. 10.1111/j.1365-2524.2006.00639.x
- Tappenden P, Hamilton J, Kaltenthaler E, et al. Nusinersen for treating spinal muscular atrophy: a single technology appraisal. Sheffield: School of Health and Related Research (ScHARR), The University of Sheffield; 2018 May 30 [cited 2022 Sep26] . Available from: https://www.nice.org.uk/guidance/ta588/documents/committee-papers
- Thompson R, Vaidya S, Teynor M. The Utility of Different Approachs to Developing Health Utilities Data in Childhood Rare Diseases – A Case Study in Spinal Muscular Atrophy (SMA). Value in Health. 2017;20(9):A725–A726. DOI:10.1016/j.jval.2017.08.1962.
- Ara R, Brazier J E. Populating an Economic Model with Health State Utility Values: Moving toward Better Practice. Value in Health. 2010;13(5):509–518. DOI:10.1111/j.1524-4733.2010.00700.x.
- Song J, Floyd F J, Seltzer M Mailick, et al. Long-Term Effects of Child Death on Parents' Health-Related Quality of Life: A Dyadic Analysis. Family Relations. 2010;59(3):269–282. DOI:10.1111/j.1741-3729.2010.00601.x.
- Thokala P, Stevenson M, Kumar VM, et al. Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US. Cost Eff Resour Alloc. 2020;18(1). DOI:10.1186/s12962-020-00234-8.
- National Institute for Health and Care Excellence (NICE). Nusinersen for treating spinal muscular atrophy [TA588]. 2019Jul 24 [cited 2023 Mar 17]. Available from https://www.nice.org.uk/guidance/ta588/resources
- Pennington B, Eaton J, Hatswell AJ, et al. Carers’ health-related quality of life in global health technology assessment: guidance, case studies and recommendations. PharmacoEconomics. 2022 ;40:837–50.
- First UK pilot study of newborn screening for spinal muscular atrophy launched in Oxford. 2022 Mar 11 [cited 2022 Sep 26]. Available from: https://www.ox.ac.uk/news/2022-03-11-first-uk-pilot-study-newborn-screening-spinal-muscular-atrophy-launched-oxford
- NHS England. Innovative Medicines Fund. 2022 [cited 2022 Sep 30]. Available from: https://www.england.nhs.uk/medicines-2/innovative-medicines-fund/#will-cancer-medicines-be-disadvantaged-by-the-creation-of-the-innovative-medicines-fund
- Aslesh T, Yokota T. Restoring SMN expression: an overview of the therapeutic developments for the treatment of spinal muscular atrophy. Cells. 2022;11:417.
- ClinicalTrials.gov [Internet]. Identifier NCT05156320, efficacy and safety of apitegromab in patients with later-onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam (SAPPHIRE). Bethesda (MD): National Library of Medicine (US). 2021 Dec 14 [cited 2022 Sep 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT05156320?term=sapphire+scholar+rock&draw=2&rank=1